STAT3 mainly acts as a signal transducer of IL-6 family cytokines and transcriptionally activates specific target genes. The recently discovered protein Protein inhibitor of activated STAT3 (PIAS3) binds directly to STAT3 and blocks transcriptional activation. In our previous report, we demonstrated that PIAS3 directly interacted with androgen receptor (AR) and affected AR-mediated gene activation. Furthermore, we also showed that AR associated with STAT3 and enhanced its activity. Here we examined molecular interactions between STAT3, PIAS3 and AR to underline the mechanism how they regulate each other. AR activation overcame the inhibitory effect on STAT3-mediated transcription by PIAS3.
INTRODUCTION
One member of the STAT family of proteins is STAT3, which is mainly activated by IL-6 family of cytokines including Leukemia inhibitory factor (LIF) and Leptin (1, 2) . Like other members of the STAT family, STAT3 is tyrosine-phosphorylated by Jak kinases, then forms a dimer and translocates into the nucleus to activate target genes (3, 4) . It has been shown that the activated STAT3 can mediate cellular transformation (5, 6, 7) and is found in numerous cancers, including prostate (7) . Furthermore, STAT3 has been recently shown to act as an oncoprotein (5) .
Protein inhibitor of activated STAT3 (PIAS3) was originally identified as a specific inhibitor of signal transducer and activator of transcription 3 (STAT3) (8, 9) . PIAS3 binds to STAT3 and inhibits its DNA-binding activity and thereby interferes with STAT3-mediated gene activation. Recently, PIAS3 has been also shown to function as a transcriptional cofactor for AR (10, 11) .
Androgen receptor (AR) mediates the effects of androgens and plays a central role in prostate cancer progression (12) . In the beginning stages of the disease, the growth of prostate cancer is dependent on androgens. This is the basis for androgen ablation therapy which results in the involution of the tumor (13) . However, in most cases, it progresses to an androgen-independent phenotype at which time there is no curative therapy available (14) .
AR activates transcription through interaction with androgen response elements (AREs) that are in the vicinity of the androgen responsive genes, such as prostate specific antigen (PSA) and probasin (PB) (12) . Recent studies have documented that IL-6 activates AR-mediated gene expression through STAT3 (15, 16, 17) .
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In our previous studies, we demonstrated that the cross-talk between IL-6 and AR signaling occurs by direct physical and functional interactions between STAT3 and AR in prostate cancer cells (17) . We also showed that PIAS3 directly interacts with AR and modify the transcriptional activity of AR (11) .
In this study, we report that AR activation overcomes the inhibitory effect on STAT3-mediated transcription by PIAS3 and an active form of AR relieves STAT3 from STAT3-PIAS3 complex formation by their physical protein-protein competition.
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MATERIALS AND METHODS
Reagents and antibodies.
Human recombinant LIF was purchased from INTERGEN (Purchase, NY). Expression vectors, HA-tagged STAT3 or Jak1, 2xARE-LUC (18), AR(1-714) (18), STAT3-LUC (19) STAT3-C(5) and FLAG-tagged PIAS3 (8) Shuai (UCLA), respectively. Myc-tagged STAT3 mutants were described previously (20) .
Anti-AR and anti-HA antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz). Anti-FLAG M2 antibody was purchased from Sigma (St Louis, MO).
Cell culture, transfections, and luciferase assays.
Human embryonic kidney carcinoma cell line, 293T cells were transfected in DMEM containing 1% FCS by the standard calcium precipitation protocol. The cells were harvested 48 h after transfection and lysed in 200 μl of PicaGene Reporter Lysis Buffer (Toyo Ink, Tokyo, Japan) and assayed for luciferase and β-galactosidase activities according to the manufacturer's instructions. Luciferase activities were normalized to the β-galactosidase activities.
Immunoprecipitation and immunoblotting.
Immunoprecipitation and Western blotting were performed as described previously (21) .
Briefly, the transfected 293T cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.3 M 7 NaCl, containing 1% NP-40, 1mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 10 μg/ml each of aprotinin, pepstatin and leupeptin). Cell lysates were immunoprecipitated with each antibody as indicated. The immunoprecipitates from cell lysates were resolved on 5-20% SDS-PAGE and transferred to Immobilon membrane (Millipore, Bedford, MA). The membranes were then probed with each antibody as indicated. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
RESULTS AND DISCUSSION
Transcriptional cross-talk between STAT3 and PIAS3, AR
We previously demonstrated that STAT3 functionally interacts with AR in prostate cancer cells (17) and a STAT3 inhibitor, PIAS3 directly interacts with AR and modify the transcriptional activity of AR (11) . However, molecular interactions between STAT3, PIAS3 and AR were still unknown. To delineate the mechanism how they regulate each other, we first access the transcriptional cross-talk between STAT3, PIAS and AR. To examine whether AR has any effect on the transcriptional inhibitory activity of PIAS3 on STAT3, we carried out transient transfection assays. STAT3-LUC, in which the α2-macroglobulin promoter drives expression of the LUC gene (19) was transfected into 293T cells in the presence of increasing amounts of PIAS3, cells were stimulated with LIF, and LUC activities were determined. As shown in Fig.1A , LIF-induced STAT3 activation was inhibited by the expression of PIAS3 in a dose-dependent manner, the result being in accordance with that previously reported (8) . When we expressed the increasing amounts of an active form of AR, AR (1-714) (18) in the presence of PIAS3 in 293T cells and stimulated with LIF ( Fig. 1A) , the inhibitory effect of PIAS3 on STAT3-mediated transcriptional activation was reversed by the expression of an active form of AR. To avoid the activation of other signaling pathways by LIF stimulation, we also used a constitutively active form of STAT3, STAT3-C (5). 293T cells were transfected with STAT3-LUC together with expression vectors for STAT3-C and/or the increasing amounts of PIAS3, and the LUC activities were measured. PIAS3 expression suppressed STAT-LUC activity induced by STAT3-C (Fig, 1B) . Furthermore, when we co-expressed the increasing amounts of AR(1-714) together with STAT3-C and PIAS3, the similar results as described above were obtained as shown in Fig. 1B .
Conversely, to assess whether STAT3 activation has an effect on the cross-talk between PIAS3 and AR, we examined the effect of STAT3 activation on the PIAS3-modified AR activation in 293T cells. AR activity was monitored by 2xARE-LUC reporter in which two copies of an androgen response element (ARE) drive expression of the LUC gene (18) . As shown in Fig.1C , PIAS3 enhanced AR-induced 2xARE-LUC activation in a dose-dependent manner in 293T cells. The enhanced AR activation by PIAS3 was slightly suppressed by the expression of the increasing amounts of STAT3-C (5).
These results indicate that AR can reverse the inhibitory effect of PIAS3 on STAT3-mediated transcriptional activation, but STAT3 has a few effect on the transcriptional cross-talk between PIAS3 and AR.
Mapping of PIAS3 or AR interacting domain on STAT3
In our previous reports, we demonstrated that either STAT3 or PIAS3 directly interacts with AR and an intact N-terminus is required for AR to interact with either STAT3 or PIAS3 (11, 17) . These results also suggested that AR interact with either STAT3 or PIAS3 in the similar region. We then examined the interacting domains on STAT3 with AR or PIAS3. To delineate the domains in the STAT3 that mediate the protein-protein interaction with AR or PIAS3, co-immunoprecipitation experiments were performed with a series of mutant STAT3 proteins. Expression vectors encoding an active form of AR(1-714) or FLAG-tagged PIAS3 and a series of Myc-tagged STAT3 mutants were transiently transfected into 293T cells.
Cells were lysed, and subjected to immunoprecipitation with an AR or an anti-FLAG antibody. Immunoprecipitates were then used in Western blot analysis with an anti-Myc antibody. As shown in Fig. 2B , both the DNA binding domain/STAT3(320-493) and the C-terminal region/STAT3(494-750) of STAT3 interacted with AR(1-714). The N-terminal domain/STAT3(1-137) or the coiled-coil domain/STAT3(138-319) did not interact with AR(1-714). Interestingly, PIAS3 also interacted with the similar regions of STAT3 (Fig.   2C ).
These results indicate that either AR or PIAS3 interacts with STAT3 via a large C-terminal region of STAT3 including the DNA binding domain.
Protein-protein interactions between STAT3 and PIAS3, AR
To further delineate the molecular mechanisms how AR can overcome the STAT3-mediated transcriptional activation by PIAS3 block, we performed co-immunoprecipitation experiments by introducing these three expression vectors into 293T cells. We also introduced Jak1 expression vector together with them to activate STAT3.
Expression vectors encoding FLAG-tagged PIAS3 and HA-tagged STAT3 together with Jak1 were transiently transfected into 293T cells. Cells were lysed, and subjected to immunoprecipitation with an anti-HA antibody. Immunoprecipitates were then used in Western blot analysis with an anti-FLAG antibody. As shown in Fig. 3, STAT3 interacted with PIAS3 strongly. Interestingly, when we expressed both HA-tagged STAT3 and FLAG-tagged PIAS3, Jak1 together with the increasing amounts of an active form of AR (1-714), the STAT3-bond PIAS1 proteins remarkably decreased in a dose-dependent manner.
These results strongly suggested AR can relieve STAT3-mediated transcriptional transactivation from PIAS3 block by their physical protein-protein competition.
Conclusions
In this report, we have shown that AR activation overcomes the inhibitory effect on Recently, a similar observation has been reported (22) . A zinc finger protein, Gfi-1, which is to act as a dominant oncogene and cooperates in the process of lymphomagenesis with Myc and Pim-1 (23) , was identified as a potential binding partner for PIAS3 using a yeast two-hybrid screening (22) . It was also shown that Gfi-1 interacts with PIAS3 and affects its function, as it is able to relieve the inhibitory effect of PIAS3 on STAT3 activity (22) , suggesting that the oncogenic potential of Gfi-1 may be at least in part mediated by an enhancement of STAT3-triggered events. Thus, Gfi-1 in the lymphoma development might be an analogue with AR in the progression of prostate cancer.
Prostate cancer frequently progresses from an initial androgen dependence to androgen independence, rendering the only effective androgen ablation therapy useless (13, 14) . The mechanism underlying the androgen-independent progression is unknown. Recent studies have shown that STAT3 may play a role in the progression of prostate cancer (24, 25) . The levels of activated STAT3 are associated with the progression of androgen-independent prostate cancer (24) . Activation of STAT3 in androgen-sensitive LNCaP prostate cancer cells results in enhancement of tumor growth in both intact and castrated male nude mice and 
